Recently, Foresite Capital announced that it had named Molly He as a venture partner. Before joining the healthcare equity company, Dr. He served as a senior director at Illumina. She brings to the company an experience of over 15 years in pharmaceutical, genomic research, and development. Jim Tananbaum, the CEO and managing director of Foresite Capital noted that Dr. He is one of the most revered scientific researchers in the field of next-generation sequencing. They were thrilled to welcome her to their team. With her broad expertise in drug development, genomics, and exceptional leadership skills, she will be an important resource to the firm. Dr. Molly will play a pivotal role in the company’s growth as they continue to diversify their portfolio.
At Illumina, she was in charge of the firm’s international protein reagent innovation and improvements. More details can be found on his LinkedIn account.
Previously, Dr. He worked for Pacific Biosciences as the head of protein sciences. She was in charge of protein reagent development for the corporation’s single molecular sequencing chemistry. In the early stages of her profession, Dr. He spent 10 years in the pharmaceutical sector, specializing on structural-based design of antibody and immune diseases. She also focused on small molecule drugs targeting cancer. Dr. He is an alumnus of Nankai University where she graduated with a bachelor’s degree in biochemistry. She holds a PhD in protein biophysics from the University of California, Los Angeles. Dr. Molly has written over 20 published papers and has over 20 patent applications as well as issued patents.
She noted that Foresite has an unmatched reputation of investing in a number of the most innovative firms in the healthcare industry. Additionally, the doctor said that she was honored to join a seasoned and dynamic team. She aims to expand the company’s portfolio regarding next-generation sequencing.
About Jim Tananbaum
Jim Tananbaum is Foresite Capital Management’s founding CEO. Through his visionary leadership, the company has successfully invested in 21 healthcare firms, including Jazz Pharmaceuticals, Amerigroup, and Amira Pharmaceuticals that was purchased by Bristol-Myers Squibb. Previously, Tananbaum held different managerial positions at Theravance and GelTex Pharmaceuticals.
For a third year in a row, Forbes named Tananbaum in the Midas List of Top Tech Investors. The Midas List honors the leading venture capitalists that make big bets on leading tech firms. In the 2017 list, Tananbaum ranked position 52.
Follow him on Twitter